Skip to content

Randomized controlled study of digital electric fire needle treatment for mild cognitive dysfunction

Randomized controlled study of digital electric fire needle treatment for mild cognitive dysfunction

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001705
Enrollment
Unknown
Registered
2025-09-11
Start date
2025-07-30
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Cognitive Dysfunction

Interventions

Treatment group (digital electric fire needling group):Digital electric fire needle Therapy
Control group (sham fire needle group):Sham fire needle treatment

Sponsors

The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1: Meet MCI diagnostic criteria, and 18 points = Montreal Cognitive Assessment Scale (MoCA) <26 points 2: Age between 40 and 85 years 3: Be clear in consciousness and have sufficient visual, auditory and language skills to undergo neuropsychological assessment 4: The ability to live daily life has not decreased significantly, i.e. (ADL less than or equal to16 points) 5: The patient or family members informed consent for this study and signed an informed consent form

Exclusion criteria

Exclusion criteria: 1: Suffering from other diseases that can cause cognitive impairment (such as encephalitis, abnormal thyroid function, intracranial space-occupying lesions, mental history, Parkinson's history, etc.) 2: Unable to cooperate with all neuropsychological scale assessors (aphasia, severe vision and hearing impairment) 3: People with serious heart disease, liver and kidney, digestive system, tumors, etc. or severe systemic infections 4: Patients with a history of alcohol and drug abuse and long-term use of drugs that affect cognitive function, such as glucocorticoids, antipsychotics, sedatives and hypnotics, etc. 5: Those with coagulation dysfunction 6: Pregnant or lactating women 7: Participating in other clinical trials 8: Refusal to sign informed consent

Design outcomes

Primary

MeasureTime frame
Montreal Cognitive Assessment;

Secondary

MeasureTime frame
Mini-Mental State Examination;Digit Span Test;Clock Drawing Task;Auditory Verbal Learning Test;Pittsburgh Sleep Quality Index;TNF-a;Brain-derived neurotrophic factor;IL-6;Nuclear factor ?B;IL-1ß;

Countries

China

Contacts

Public ContactWang Shuxin

The First Affiliated Hospital of Guangzhou University of Chinese Medicine

widiot@126.com+86 136 6028 5076

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026